scholarly journals Biotechnology Application of Therapeutic Antibody Drug Discovery and Preparation

OALib ◽  
2021 ◽  
Vol 08 (08) ◽  
pp. 1-6
Author(s):  
Huilin Cao
Antibodies ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 12 ◽  
Author(s):  
Jordan Graves ◽  
Jacob Byerly ◽  
Eduardo Priego ◽  
Naren Makkapati ◽  
S. Vince Parish ◽  
...  

Driven by its successes across domains such as computer vision and natural language processing, deep learning has recently entered the field of biology by aiding in cellular image classification, finding genomic connections, and advancing drug discovery. In drug discovery and protein engineering, a major goal is to design a molecule that will perform a useful function as a therapeutic drug. Typically, the focus has been on small molecules, but new approaches have been developed to apply these same principles of deep learning to biologics, such as antibodies. Here we give a brief background of deep learning as it applies to antibody drug development, and an in-depth explanation of several deep learning algorithms that have been proposed to solve aspects of both protein design in general, and antibody design in particular.


2004 ◽  
Vol 64 (3) ◽  
pp. 781-788 ◽  
Author(s):  
Weiguang Mao ◽  
Elizabeth Luis ◽  
Sarajane Ross ◽  
Johnny Silva ◽  
Christine Tan ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15620-e15620
Author(s):  
William Michael Schopperle

e15620 Background: As of today, there are no current beneficial clinical therapeutic cancer treatments for advance metastatic gastric or pancreatic cancers. A new approach to finding effective and meaningful drugs to treat these cancers is based an emerging hypothesis that cancer is a reprogramming disease and its origin and development is due to retrograde-like malignant cells with primitive and embryonic characteristics which are responsible for the dissemination of the disease and the almost universal clinical response of tumor resistance when treated with standard current therapies. Methods: A pluripotent human germ cell tumor cell line, TERA-1, was used to isolate and purify embryonic antigens which where used to immunized mice and, with standard B-cell hybridoma technology, to generate monoclonal antibodies. Antibodies were screened by ELISA and SDS-PAGE Western blotting to identify antibodies specific to gastric and pancreatic cancers but not to normal tissues. A second assay was used to screen the potential of the antibodies to function as antibody-drug-conjugate therapeutics against cancer. Results: A lead therapeutic antibody, Bstrongomab, was identified in the antibody screens: it is positive for gastric and pancreatic cancers but does not react with normal tissues. Bstrongomab is an IgG1 monoclonal antibody which has high affinity and specificity to the embryonic target TRA-1-60. TRA-1-60 is a carbohydrate molecule which is highly expressed in normal embryonic stem cells and not expressed in normal tissues but is re-expressed in gastric and pancreatic cancers. Immunohistochemical tissue staining studies show TRA-1-60 is expressed in gastric and pancreatic cancers. Recent published scientific reports confirm this finding. A human/mouse therapeutic version of Bstrongomab was developed - Bstrongximab - and used to generate a novel therapeutic antibody-drug-conjugate with Bstongximab and the toxic payload MMAE (Monomethyl auristatin E). Pre-clinical i n-vitro and in-vivo studies show Bstrongximab-MMAE is a potent drug for gastric and pancreatic cancers. Conclusions: Bstrongximab is a novel IgG1 human/mouse chimeric therapeutic antibody that targets TRA-1-60, a novel and yet to be tried cancer target that is highly expressed in gastric and pancreatic cancers but not in normal tissues. Bstrongximab-MMAE has the potential to be a first-in-class cancer therapeutic that provides real and meaningful benefits to patients with metastatic gastric and pancreatic cancers.


Viruses ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 178
Author(s):  
Kazuya Nagano ◽  
Yasuo Tsutsumi

Antibody drugs with a high affinity and specificity are effective and safe for intractable diseases, such as cancers and autoimmune diseases. Furthermore, they have played a central role in drug discovery, currently accounting for eight of the top 20 pharmaceutical products worldwide by sales. Forty years ago, clinical trials on antibody drugs that were thought to be a magic bullet failed, partly due to the immunogenicity of monoclonal antibodies produced in mice. The recent breakthrough in antibody drugs is largely because of the contribution of phage display technology. Here, we reviewed the importance of phage display technology as a powerful platform for antibody drug discovery from various perspectives, such as the development of human monoclonal antibodies, affinity enhancement of monoclonal antibodies, and the identification of therapeutic targets for antibody drugs.


2003 ◽  
Vol 25 (6) ◽  
pp. 35-37
Author(s):  
Andy Porter

In recent years, antibody engineering has become one of the most important and most productive routes to drug discovery. It is now widely accepted that this approach can reduce development times and increase potential success, compared with classical drug development. Until recently, the isolation and production of therapeutic-antibody products has been concentrated on larger, protein targets. A research team at Haptogen has now overcome the significant technical difficulties that have been associated with raising antibodies to the smallest of small molecules — bioactive haptens — and, for the first time, anti-hapten therapeutics can be realized. Here, we outline our pioneering approach to antibody engineering and present the results of early work in the important field of anti-infective therapy.


Sign in / Sign up

Export Citation Format

Share Document